Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use

  • García-Muñoz, Elisabeth
  • Vives Armengol, Joaquim
Teixit adipós; Medul·la òssia; Cèl·lules estromals mesenquimals multipotents, Tejido adiposo; Médula ósea; Células estromales mesenquimales multipotentes, Adipose tissue; Bone marrow; Multipotent mesenchymal stromal cells, Multipotent mesenchymal stromal cells (MSCs) are currently the most extensively studied type of adult stem cells in advanced stages of development in the field of regenerative medicine. The biological properties of MSCs have generated great hope for their therapeutic use in degenerative and autoimmune conditions that, at present, lack effective treatment options. Over the last decades, MSCs have been typically obtained from adult bone marrow, but the extraction process is highly invasive and the quality and numbers of isolated cells is drastically influenced by patient age, medication and associated comorbidities. Therefore, there is currently an open discussion on the convenience of allogeneic over autologous treatments, despite potential disadvantages such as rejection by the host. This shift to the allogeneic setting entails the need for high production of MSCs to ensure availability of sufficient cell numbers for transplantation, and therefore making the search for alternative tissue sources of highly proliferative MSC cultures with low levels of senescence occurrence, which is one of the greatest current challenges in the scale up of therapeutic cell bioprocessing. Herein we (i) present the main isolation protocols of MSCs from bone marrow, adipose tissue and Wharton’s jelly of the umbilical cord; and (ii) compare their qualities from a bioprocess standpoint, addressing both quality and regulatory aspects, in view of their anticipated clinical use., This work has been developed in the context of the Spanish Cell Therapy Network (TerCel, expedient number: RD16/0011/0028) and project PI19/01788, which is funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Prat-Vidal, Cristina
Gelatina de Wharton; Enginyeria de teixits cardíacs; Infart de miocardi, Gelatina de Wharton; Ingeniería de tejidos cardíacos; Infarto de miocardio, Wharton’s jelly; Cardiac tissue engineering; Myocardial infarction, Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management., This work has been developed in the context of ADVANCE(CAT) with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) and the European Community under the Catalonian ERDF operational program (European Regional Development Fund) 2014–2020, Generalitat de Catalunya (Departament de Salut) PERIS Acció Instrumental de Programes de Recerca Orientats (SLT002/16/00234), Spanish Society of Cardiology, Catalan Society of Cardiology, Fundació bancària La Caixa, CIBER Cardiovascular (CB16/11/00403) and by the Spanish Cell Therapy Network (TerCel, expedient numbers: RD16/0011/0006 & RD16/0011/0028). Projects PI19/01788, PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, ICI20/00135 are funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe. Projects SAF2017-84324-C2-1-R and PID2019-110137RB-I00 are funded the Spanish Ministry of Economy and Competitiveness-MICINN. Our laboratories are awarded by the Generalitat de Catalunya’s AGAUR as Consolidated Research Groups (references 2017-SGR-483, 2017-SGR-719 and 2019PROD00122), and by the Catalan Heath Institute.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance

  • Vives Armengol, Joaquim
  • Sòria, Maria Glòria
  • McGrath, Eoin
  • Magri, Mara
Integrated management system; Quality compliance; Quality standards, Sistema de gestión integrado; Cumplimiento de la calidad; Estándares de calidad, Sistema de gestió integrat; Compliment de la qualitat; Estàndards de qualitat, Cell therapies are required to meet with compulsory regulations that co-exist with other optional standards and guidelines that together compose a complex quality management system. Indeed, reliable insights on the mechanisms of action and safety of novel cell-based therapies require adherence to solid quality management structures in all steps of the value chain, from early research and tissue procurement to clinical trials and biovigilance, thus guaranteeing reproducibility and solid foundations for better science and improved clinical practice. Herein we present the concept of the quality ecosystem as a tool to understand and assist all stakeholders involved in developing and structuring the integration of standards as novel developments are taking place. We conclude that the various quality management initiatives can all be thought about under the umbrella of an ecosystem., Work in JV’s laboratory is supported by the Spanish Advanced Therapy Network (TERAV, expedient No. RD21/0017/0022), awarded by the Generalitat de Catalunya as Consolidated Research Group (ref. 2017SGR719) and funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

  • Cabrera Perez, Raquel
  • Gámez-Valero, Ana
  • Rojas-Márquez, Raquel
  • Borràs, Francesc Enric
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Monguió-Tortajada, Marta
Cèl·lules estromals mesenquimals; Gelatina de Wharton; Diferenciació osteogènica, Células estromales mesenquimales; Gelatina de Wharton; Diferenciación osteogénica, Mesenchymal stromal cells, Wharton’s jelly; Osteogenic differentiation, Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions., Work in our laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788), Fundació la Marató de TV3 (expedient number: 122831), and ISCIII-REDinREN (RD16/0009 Feder Funds), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational programme (European Regional Development Fund) 2014-2020. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya). Our laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Groups (ref. 2017-SGR-719, 2017-SGR-301 and 2017-SGR-483).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton's jelly mesenchymal stromal cells, Mechanisms and implications for bioprocess development and clinical application

  • Cabrera-Pérez, Raquel|||0000-0002-4858-0142
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Rojas-Márquez, R.
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Background: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton's jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use

  • García Muñoz, Elisabeth
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Multipotent mesenchymal stromal cells (MSCs) are currently the most extensively studied type of adult stem cells in advanced stages of development in the field of regenerative medicine. The biological properties of MSCs have generated great hope for their therapeutic use in degenerative and autoimmune conditions that, at present, lack effective treatment options. Over the last decades, MSCs have been typically obtained from adult bone marrow, but the extraction process is highly invasive and the quality and numbers of isolated cells is drastically influenced by patient age, medication and associated comorbidities. Therefore, there is currently an open discussion on the convenience of allogeneic over autologous treatments, despite potential disadvantages such as rejection by the host. This shift to the allogeneic setting entails the need for high production of MSCs to ensure availability of sufficient cell numbers for transplantation, and therefore making the search for alternative tissue sources of highly proliferative MSC cultures with low levels of senescence occurrence, which is one of the greatest current challenges in the scale up of therapeutic cell bioprocessing. Herein we (i) present the main isolation protocols of MSCs from bone marrow, adipose tissue and Wharton's jelly of the umbilical cord; and (ii) compare their qualities from a bioprocess standpoint, addressing both quality and regulatory aspects, in view of their anticipated clinical use.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit, an experienced view

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago|||0000-0003-4063-9661
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The challenge of developing human 3D organoids into medicines

  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Batlle Morera, Laura|||0000-0002-6924-9002
The capacity of organoids to generate complex 3D structures resembling organs is revolutionizing the fields of developmental and stem cell biology. We are currently establishing the foundations for translational applications of organoids such as drug screening, personalized medicine and launching the future of cell therapy using organoids. However, clinical translation of organoids into cell replacement therapies is halted due to (A) a few preclinical studies demonstrating their efficacy and (B) the lack of robust, reproducible, and scalable methods of production in compliance with current pharmaceutical standards. In this issue of Stem Cell Research & Therapy [ref], Dossena and collaborators present a validated bioprocess design for large-scale production of human pancreatic organoids from cadaveric tissue in accordance with current good manufacturing practice. The authors also propose a set of specifications of starting materials and critical quality attributes of final products that are of interest to other developments provided that this type of medicines are different than any other medicinal product due to their complex composition and living nature of the active ingredient. Although large-scale production of functional cells secreting insulin is still a challenge, the development of methods such as the one presented by Dossena and collaborators contributes to move toward clinical use of organoids in the treatment of type 1 diabetes and opens avenues for future clinical use of organoids in degenerative pathologies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical translation of mesenchymal stromal cell extracellular vesicles, Considerations on scientific rationale and production requisites

  • Courageux, Yvan|||0000-0002-1484-2677
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
The present paper is a commentary to 'Identification and characterization of hADSC - derived exosome proteins from different isolation methods ' (Huang et al. 2021; ). Given the enthusiasm for the potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs), some considerations deserve attention as they move through successive stages of research and application into humans. We herein remark the prerequisite of generating that evidence ensuring a high consistency in safety, composition and biological activity of the intended MSC-EV preparations, and the suitability of disparate isolation techniques to produce efficacious EV preparations and fulfil requirements for standardized clinical-grade biomanufacturing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain), An Opportunity for Integrating Standards and Streamlining Quality Compliance

  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Sòria, Maria Glòria
  • McGrath, Eoin|||0000-0002-1956-037X
  • Magri, Mara
Cell therapies are required to meet with compulsory regulations that co-exist with other optional standards and guidelines that together compose a complex quality management system. Indeed, reliable insights on the mechanisms of action and safety of novel cell-based therapies require adherence to solid quality management structures in all steps of the value chain, from early research and tissue procurement to clinical trials and biovigilance, thus guaranteeing reproducibility and solid foundations for better science and improved clinical practice. Herein we present the concept of the quality ecosystem as a tool to understand and assist all stakeholders involved in developing and structuring the integration of standards as novel developments are taking place. We conclude that the various quality management initiatives can all be thought about under the umbrella of an ecosystem.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use

  • García-Muñoz, Elisabeth
  • Vives Armengol, Joaquim
Teixit adipós; Medul·la òssia; Cèl·lules estromals mesenquimals multipotents, Tejido adiposo; Médula ósea; Células estromales mesenquimales multipotentes, Adipose tissue; Bone marrow; Multipotent mesenchymal stromal cells, Multipotent mesenchymal stromal cells (MSCs) are currently the most extensively studied type of adult stem cells in advanced stages of development in the field of regenerative medicine. The biological properties of MSCs have generated great hope for their therapeutic use in degenerative and autoimmune conditions that, at present, lack effective treatment options. Over the last decades, MSCs have been typically obtained from adult bone marrow, but the extraction process is highly invasive and the quality and numbers of isolated cells is drastically influenced by patient age, medication and associated comorbidities. Therefore, there is currently an open discussion on the convenience of allogeneic over autologous treatments, despite potential disadvantages such as rejection by the host. This shift to the allogeneic setting entails the need for high production of MSCs to ensure availability of sufficient cell numbers for transplantation, and therefore making the search for alternative tissue sources of highly proliferative MSC cultures with low levels of senescence occurrence, which is one of the greatest current challenges in the scale up of therapeutic cell bioprocessing. Herein we (i) present the main isolation protocols of MSCs from bone marrow, adipose tissue and Wharton’s jelly of the umbilical cord; and (ii) compare their qualities from a bioprocess standpoint, addressing both quality and regulatory aspects, in view of their anticipated clinical use., This work has been developed in the context of the Spanish Cell Therapy Network (TerCel, expedient number: RD16/0011/0028) and project PI19/01788, which is funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Prat-Vidal, Cristina
Gelatina de Wharton; Enginyeria de teixits cardíacs; Infart de miocardi, Gelatina de Wharton; Ingeniería de tejidos cardíacos; Infarto de miocardio, Wharton’s jelly; Cardiac tissue engineering; Myocardial infarction, Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management., This work has been developed in the context of ADVANCE(CAT) with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) and the European Community under the Catalonian ERDF operational program (European Regional Development Fund) 2014–2020, Generalitat de Catalunya (Departament de Salut) PERIS Acció Instrumental de Programes de Recerca Orientats (SLT002/16/00234), Spanish Society of Cardiology, Catalan Society of Cardiology, Fundació bancària La Caixa, CIBER Cardiovascular (CB16/11/00403) and by the Spanish Cell Therapy Network (TerCel, expedient numbers: RD16/0011/0006 & RD16/0011/0028). Projects PI19/01788, PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, ICI20/00135 are funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe. Projects SAF2017-84324-C2-1-R and PID2019-110137RB-I00 are funded the Spanish Ministry of Economy and Competitiveness-MICINN. Our laboratories are awarded by the Generalitat de Catalunya’s AGAUR as Consolidated Research Groups (references 2017-SGR-483, 2017-SGR-719 and 2019PROD00122), and by the Catalan Heath Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

  • Cabrera Perez, Raquel
  • Gámez-Valero, Ana
  • Rojas-Márquez, Raquel
  • Borràs, Francesc Enric
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Monguió-Tortajada, Marta
Cèl·lules estromals mesenquimals; Gelatina de Wharton; Diferenciació osteogènica, Células estromales mesenquimales; Gelatina de Wharton; Diferenciación osteogénica, Mesenchymal stromal cells, Wharton’s jelly; Osteogenic differentiation, Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions., Work in our laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788), Fundació la Marató de TV3 (expedient number: 122831), and ISCIII-REDinREN (RD16/0009 Feder Funds), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational programme (European Regional Development Fund) 2014-2020. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya). Our laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Groups (ref. 2017-SGR-719, 2017-SGR-301 and 2017-SGR-483).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance

  • Vives Armengol, Joaquim
  • Sòria, Maria Glòria
  • McGrath, Eoin
  • Magri, Mara
Integrated management system; Quality compliance; Quality standards, Sistema de gestión integrado; Cumplimiento de la calidad; Estándares de calidad, Sistema de gestió integrat; Compliment de la qualitat; Estàndards de qualitat, Cell therapies are required to meet with compulsory regulations that co-exist with other optional standards and guidelines that together compose a complex quality management system. Indeed, reliable insights on the mechanisms of action and safety of novel cell-based therapies require adherence to solid quality management structures in all steps of the value chain, from early research and tissue procurement to clinical trials and biovigilance, thus guaranteeing reproducibility and solid foundations for better science and improved clinical practice. Herein we present the concept of the quality ecosystem as a tool to understand and assist all stakeholders involved in developing and structuring the integration of standards as novel developments are taking place. We conclude that the various quality management initiatives can all be thought about under the umbrella of an ecosystem., Work in JV’s laboratory is supported by the Spanish Advanced Therapy Network (TERAV, expedient No. RD21/0017/0022), awarded by the Generalitat de Catalunya as Consolidated Research Group (ref. 2017SGR719) and funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788).